Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296753 | 0.90 | HDAC3 (0.47) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1110607 | 0.84 | CA12 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL281590 | 0.84 | RAB9A (0.59) | PDK1PDK2PDK3PDK4MAPK1 | |
| SCHEMBL29029431 | 0.83 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL29991055 | 0.83 | NPC1 (0.55) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL27833511 | 0.83 | NPC1 (0.55) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL27828678 | 0.82 | CYP17A1 (0.48) | HDAC3HDAC1HDAC2HDAC8PDK1 | |
| SCHEMBL2481722 | 0.81 | HDAC3 (0.47) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3892771 | 0.81 | ALDH1A1 (0.52) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL999347 | 0.81 | KMT2A (0.61) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114188658-B | Film, preparation method thereof and battery | 深圳中兴新材技术股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-112480116-B | PKB inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-103987707-B | The base heterocyclic radical benzamide compound of pyrazoles 4 and application method | 霍夫曼-拉罗奇有限公司 | 2017-11-07 | — | — | CN | disclosed |
| CN-103748086-B | Pyridine and pyrazines derivatives | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| CN-104230900-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-12-24 | — | — | CN | disclosed |
| CN-104211713-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-12-17 | — | — | CN | disclosed |
| CN-104211689-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-12-17 | — | — | CN | disclosed |
| CN-104016971-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-09-03 | — | — | CN | disclosed |
| CN-103977406-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-08-13 | — | — | CN | disclosed |
| CN-102596936-B | Antiviral compounds | GILEAD SCIENCES INC | 2014-06-11 | — | — | CN | disclosed |
| US-8492543-B2 | Method for producing quinazoline derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| CN-102596936-A | Antiviral compounds | GILEAD SCIENCES INC | 2012-07-18 | — | — | CN | disclosed |
| EP-2202229-B1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MAN CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| CN-102333757-A | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2189450-B1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110152521-A1 | Method for Producing Quinazoline Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| CN-102076331-A | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC | 2011-05-25 | — | — | CN | disclosed |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2202229-A1 | NOVEL PREPARATION FOR EXTERNAL USE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2189450-A1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152521-A1 | Method for Producing Quinazoline Derivative | HNMT, AZI2, GNMT | HDAC3 1988/4885HDAC1 1811/4885HDAC2 1434/4885 |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | SLC26A4, SLC6A15, SLC6A19 | HDAC3 2422/4885HDAC1 1344/4885HDAC2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.